- Home
- GTN vs MLTX Comparison
GTN vs MLTX Comparison
Compare GTN & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GTN
- MLTX
- Stock Information
- Founded
- GTN 1897
- MLTX 2021
- Country
- GTN United States
- MLTX Switzerland
- Employees
- GTN N/A
- MLTX N/A
- Industry
- GTN Broadcasting
- MLTX Biotechnology: Pharmaceutical Preparations
- Sector
- GTN Industrials
- MLTX Health Care
- Exchange
- GTN Nasdaq
- MLTX Nasdaq
- Market Cap
- GTN 592.1M
- MLTX 535.3M
- IPO Year
- GTN N/A
- MLTX N/A
- Fundamental
- Price
- GTN $5.66
- MLTX $8.66
- Analyst Decision
- GTN Strong Buy
- MLTX Buy
- Analyst Count
- GTN 4
- MLTX 9
- Target Price
- GTN $6.88
- MLTX $37.63
- AVG Volume (30 Days)
- GTN 1.1M
- MLTX 9.0M
- Earning Date
- GTN 11-07-2025
- MLTX 11-06-2025
- Dividend Yield
- GTN 5.65%
- MLTX N/A
- EPS Growth
- GTN 1482.23
- MLTX N/A
- EPS
- GTN 1.53
- MLTX N/A
- Revenue
- GTN $3,549,000,000.00
- MLTX N/A
- Revenue This Year
- GTN N/A
- MLTX N/A
- Revenue Next Year
- GTN $13.18
- MLTX N/A
- P/E Ratio
- GTN $3.70
- MLTX N/A
- Revenue Growth
- GTN 7.03
- MLTX N/A
- 52 Week Low
- GTN $2.91
- MLTX $5.95
- 52 Week High
- GTN $6.31
- MLTX $62.75
- Technical
- Relative Strength Index (RSI)
- GTN 48.71
- MLTX 21.83
- Support Level
- GTN $5.60
- MLTX $6.56
- Resistance Level
- GTN $5.86
- MLTX $7.48
- Average True Range (ATR)
- GTN 0.22
- MLTX 2.39
- MACD
- GTN -0.02
- MLTX -5.00
- Stochastic Oscillator
- GTN 43.44
- MLTX 4.77
About GTN Gray Television Inc.
Gray Media Inc is a multimedia company. The company owns and operates local television stations and digital assets. It also owns Gray Digital Media, a full-service digital agency offering national and local clients digital marketing strategies with digital products and services. Its additional media properties include video production companies Raycom Sports, Tupelo Media Group, and PowerNation Studios, and studio production facilities Assembly Atlanta and Third Rail Studios.
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.